^
    Back
    Association details:
    Biomarker:TGFB1 elevation
    Cancer:Hepatocellular Cancer
    Drug:sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) +
    galunisertib (LY2157299) (Phosphotransferase inhibitor, TGF-β1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Transl Gastroenterol
    Title:

    A Phase 2 Study of Galunisertib (TGF-ß1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

    Published date:
    07/01/2019
    Excerpt:
    Patients with baseline AFP ≥ 400 ng/mL or patients with baseline TGF-β1 ≥ baseline median (1956 pg/mL) demonstrated trends toward longer TTP.
    DOI:
    10.14309/ctg.0000000000000056
    Trial ID:
    NCT01246986